- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05557799
Photobiomodulation in Post Menopause Genitourinary Syndrome
September 27, 2022 updated by: Sandra Kalil Bussadori, University of Nove de Julho
Photobiomodulation in Post Menopause Genitourinary Syndrome - Study Protocol for a Randomized, Double-blind, Controlled Clinical Trial
The goal of this project is to evaluate the clinical response of patients with symptoms of genitourinary menopause syndrome after the application of photobiomodulation in the vagina and its introit.
METHOD: In this randomized, double-blind, placebo-controlled study protocol, women over 50 years of age who are in the postmenopausal period (amenorrhea for at least 12 months, with no pathology involved) with one or more symptoms of PGS will be selected.
Participants included in the study will be randomly divided into two groups: group A, which will receive photobiomodulation with a vaginal diode laser and its introit and group B (placebo) with the laser device turned off.
Both treatments will be maintained for 4 consecutive weeks.The treatment group (n=30) will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for the 40s in each site, once per week for 4 weeks.
The Placebo Group (n=30) will be handled as treated, but with the laser turned off.
Quality of life will be analyzed using the female sexual functioning index (FSFI-6), the urinary incontinence questionnaire (ICIQ-SF), the intensity of menopausal symptoms will be evaluated using a visual analogue scale (VAS), the vulvo vaginal atrophy will be measured by the Vaginal Health Index (VHI) and compared between groups.
Also, the vaginal temperature will be measured using a thermal camera, as well as the pressure of the pelvic floor force (vaginal dynamometer) and a 1-hour Pad Test will be performed to quantify the urinary loss.
The data will be tested for normality using the Shapiro Wilks test and, if they present a parametric distribution, they will be represented by means of their respective means and standard deviations.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 2
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women over 50 years of age who are in the postmenopausal period (amenorrhea for at least 12 months, with no pathology involved);
- With one or more symptoms of UGS (dyspareunia, dryness, irritation and vaginal burning and/or discomfort, vaginal atrophy, vaginal and vulvar dryness, dysuria, frequency, recurrent urinary infections);
- With complaints of stress and/or urge urinary incontinence;
- Who have cervical cytopathology (Pap smear) within the normal range performed in the last year and are not in use of hormonal medication to treat menopausal symptoms in the last 6 months.
Exclusion Criteria:
- Participants with explicit refusal of the patient to participate in the researc;
- History of bilateral oophorectomy and diseases such as: recent AMI (Acute Myocardial Infarction), neoplasms, history of thrombosis, liver failure, uncontrolled genital bleeding, genital condylomatosis, active genital herpes, lower genital tract surgeries that make treatment impossible.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Photobiomodulation group
Participants in this group will receive photobiomodulation with a vaginal diode laser and its introit.
|
The treatment group will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for 40s in each site, once per week for 4 weeks.
|
Placebo Comparator: Placebo group
Participants in this group will receive simulated photobiomodulation, with the laser device turned off.
|
The Placebo Group will receive the same four consecutive applications, but with the laser turned off.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the Female Sexual Function Index (FSFI)
Time Frame: Baseline and the 4 weeks of treatment.
|
The FSFI or female sexual function index is a specific and multidimensional questionnaire to assess female sexual response, accessing 6 domains: desire, arousal, lubrication, orgasm, satisfaction and pain evaluated in 19 questions about sexual activity in the last 4 weeks.
In order to obtain the total score of the scale, the scores for each domain are added up, and for higher scores, better sexual function is considered, and the threshold for sexual dysfunction is a score of 2678.
Based on the value of the total score, it would be possible discriminate between populations at higher and lower risk of experiencing sexual dysfunction.
|
Baseline and the 4 weeks of treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF)
Time Frame: Baseline and the 4 weeks of treatment.
|
This questionnaire has a score from zero to 21 points, with zero indicating the absence of symptoms and the greater the sum of the points, the greater the impact and severity of urinary incontinence (UI) symptoms.
The maximum sum of the response values indicates a score of 21 points, referring to a high impact of UI on the individual's life.
|
Baseline and the 4 weeks of treatment.
|
Changes in the Vaginal Health Index Score
Time Frame: Baseline and the 4 weeks of treatment.
|
It consists of a clinical analysis during the speculum examination of 5 parameters: elasticity, pH, mucosal appearance, humidity and the presence of vaginal secretion.
Each aspect evaluated receives a score, which varies from 1 to 5. The score may vary from 5 to 25, and a diagnosis of Vulvo Vaginal Atrophy (VVA) is considered when the values are less than or equal to 15, the maximum score of 25 points means absence of clinical signs of vulvovaginal atrophy.
This assessment will be performed by a qualified professional during the physical examination.
|
Baseline and the 4 weeks of treatment.
|
Changes in the Vaginal pH
Time Frame: Baseline and the 4 weeks of treatment.
|
The evaluation of the vaginal pH will be carried out through a pH indicator strip, which when inserted in the middle third of the vagina in contact with the mucosa, has the color of the strip changed.
Measurement of the vaginal cul-de-sac is avoided, because contact with mucus, blood or semen can alter the reading.
The nitrazine tape must remain in contact with the vaginal wall for 5 seconds for later checking the pH on the colorimetric scale provided by the manufacturer.
Normal vaginal pH is acidic, during menacme, it should be maintained between 3.8 and 4.5.
|
Baseline and the 4 weeks of treatment.
|
Changes in Pain using a Visual Analog Scale (VAS)
Time Frame: Baseline and the 4 weeks of treatment.
|
A VAS will be used to evaluate the vaginal complaints of the participants.
They will receive a figure of a ruler with marks from 0 to 10, whose one end indicates complete absence of symptoms and the other indicates the worst possible symptom.
For analysis of the Visual and Analog Scale of Symptoms of Genitourinary Syndrome (GUS) (VAS - SGU), the sum of one to twelve points will classify the symptoms from mild to severe.
|
Baseline and the 4 weeks of treatment.
|
Changes in the Pelvic Floor Muscles (PFMs)
Time Frame: Baseline and once a week for 4 weeks
|
The pressure sensor (dynamometer) will be introduced into the vaginal canal, and the resting vaginal pressure (resting muscles) will be quantified.
The device will be calibrated, zeroed and it will be asked for the participant to contract their PFMs inwards and upwards as hard as possible 3 times and maintain the contraction for at least five seconds (maximum vaginal pressure), with an interval of 30 seconds between each pull.
|
Baseline and once a week for 4 weeks
|
Changes in Urinary Loss using Ped-Test
Time Frame: Baseline, the 4 weeks of treatment and 90 days after treatment.
|
The procedure for performing the Ped-test will be as follows: initially, the participant will be asked to place an absorbent with a previously measured weight close to the external urethral meatus.
Then, she will be given a 500 mL bottle of water to drink and wait for 15 minutes.
Afterwards, the participant will be asked to perform some actions simulating activities of daily living.
After carrying out the proposed activities, the absorbent will be removed and weighed on a precision scale, with a minimum reading of 0.1 mg and a maximum capacity of 220 g.
Urinary losses are evaluated and classified as follows: losses of up to 1 g are considered insignificant; between 1.1 and 9.9 g are classified as light losses; between 10 and 49.9 g are moderate losses; and above 50 g, severe losses.
|
Baseline, the 4 weeks of treatment and 90 days after treatment.
|
Changes in Vulva Temperature
Time Frame: Baseline and and once a week for 4 weeks
|
The temperature of the vulva, in Celsius degrees, will be evaluated at the eight points of radiation in the vulvar region, with a digital infrared thermometer, which will allow measurement without physical contact.
The average of the eight readings will be calculated before and after the diode laser procedure in the 4 consecutive weekly sessions.
|
Baseline and and once a week for 4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 30, 2022
Primary Completion (Anticipated)
June 30, 2023
Study Completion (Anticipated)
July 30, 2023
Study Registration Dates
First Submitted
September 23, 2022
First Submitted That Met QC Criteria
September 27, 2022
First Posted (Actual)
September 28, 2022
Study Record Updates
Last Update Posted (Actual)
September 28, 2022
Last Update Submitted That Met QC Criteria
September 27, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- SGPM
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postmenopausal Symptoms
-
Fundació EurecatCompletedMenopause | Postmenopausal Symptoms | Postmenopausal DisorderSpain
-
Merck Sharp & Dohme LLCCompletedPostmenopausal Symptoms
-
University Hospital Inselspital, BerneRecruitingPostmenopausal | Postmenopausal FlushingSwitzerland
-
Milton S. Hershey Medical CenterNot yet recruitingCardiovascular Diseases | Postmenopausal Symptoms
-
F&C Licorice LtdUnknownVaginal Dryness | Postmenopausal SymptomsIsrael
-
Hend HamdyNot yet recruiting
-
University of Erlangen-Nürnberg Medical SchoolElsbeth-Bonhoff-Stiftung, BerlinTerminatedPostmenopausalGermany
-
Warner ChilcottSanofiCompletedPostmenopausalUnited States, Poland, Canada, Croatia, Netherlands
-
Federal University of São PauloUnknownPostmenopausal SymptomsBrazil
-
Mayo ClinicCompletedPostmenopausalUnited States
Clinical Trials on Photobiomodulation
-
University of Nove de JulhoNot yet recruiting
-
University of Nove de JulhoUnknownSoft Tissue Injuries
-
University of Nove de JulhoCompletedTemporomandibular DisordersBrazil
-
University of Nove de JulhoUnknownTemporomandibular DisorderBrazil
-
Quietmind FoundationMaculume Ltd.Completed
-
University of Nove de JulhoRecruiting
-
University of Nove de JulhoUnknownOrthodontic Appliance Complication
-
University of Nove de JulhoNot yet recruitingPhotobiomodulation | Dental HypersensitivityBrazil
-
University of Nove de JulhoNot yet recruiting
-
University of Nove de JulhoRecruiting